← Human Trials & Peer-Reviewed Studies
Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea
Plain-language guide to PMID 22716195 (2013): single-blind and placebo-controlled clinical trial study of Exenatide.
Key Facts
- PMID
- 22716195
- Journal
- Journal of sleep research
- Year
- 2013
- Study type
- Clinical Trial
- Authors
- Idris I et al. (5 authors)
- DOI
- 10.1111/j.1365-2869.2012.01030.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exenatide, published as a clinical trial.
The researchers investigate the effects of exenatide on excessive daytime sleepiness (EDS), driving performance and depression score in patients with type 2 diabetes with EDS.
Mean (±standard error of the mean) age, body mass index (kg m(2) ) and HbA1c [mmol mol(-1) (%)] of patients at baseline were 50 ± 4.9 years, 37.6 ± 1.1 and 65 ± 19 (8.06 ± 0.41), respectively.
Who Took Part
PubMed indexes the participants as middle-aged adults, men only.
Eight obese patients with diabetes but without obstructive sleep apnoea (OSA) participated in a placebo-controlled single-blind study during which multiple wakefulness and sleep latency test, Epworth score, driving performance, depression score, fasting glucose and glycated haemoglobin (HbA1c) levels were assessed at baseline, end of placebo and treatment phase at baseline and after 22 weeks of treatment.
How the Study Was Run
The design is described as single-blind and placebo-controlled.
In this single-blind Exenatide study one party knew the assignments and the other did not.
The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.
The methods mention a period of 22 weeks.
What Was Measured
The researchers investigate the effects of exenatide on excessive daytime sleepiness (EDS), driving performance and depression score in patients with type 2 diabetes with EDS.
The subject headings attached to it are Automobile Driving, C-Reactive Protein, Depression, Diabetes Mellitus, Type 2, Disorders of Excessive Somnolence, Exenatide and Health Status.
What This Means in Plain Language
The paper is a single-blind and placebo-controlled study of Exenatide over 22 weeks.
The publication is from 2013 (Journal of sleep research), a journal based in England.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.